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Introduction {#sec1}
============

ATP binding cassette (ABC) transporters are a superfamily of membrane proteins that couple the hydrolysis of ATP to the translocation of a diverse range of molecules across lipid bilayers of biological membranes. The basic ABC transporter architecture consists of four core domains: two transmembrane domains (TMDs), and two nucleotide binding domains (NBDs). The two TMDs interact to form a central path, allowing the substrate to be either imported into, or exported out of, the cytoplasm. The NBDs contain ATP binding pockets with ATPase activity: ATP hydrolysis provides the energy required for conformational changes that enable passage of substrates through the TMDs ([@bib36]). ABC exporters are typically homodimers, in which TMDs and NBDs are encoded by a single protein chain ([@bib10]). In contrast, importers have a tetrameric structure with their TMDs and NBDs expressed as separate proteins, present exclusively in internal membranes of prokaryotes and archaea. Whereas NBDs are structurally similar and contain highly conserved motifs, the TMDs of different transporters vary widely in sequence and structure, a feature linked to different mechanisms of transport.

Depending on the fold of the TMDs, ABC importers can be classified as type I, type II, or energy-coupling factor transporters identified recently ([@bib39], [@bib24], [@bib37]). Type I and type II importers require a periplasmic substrate-binding protein (SBP) for their function. SBPs capture substrates and deliver them to the transporters allowing the passage of the ligand through the lipid bilayer ([@bib26]). The molybdate transporter ModBC-A ([@bib14]), along with the maltose transporter MalFGK~2~ ([@bib8]) and vitamin B~12~ transporter BtuCD-F, are the most studied type I and type II importers, respectively ([@bib25]). In addition to different numbers of TMDs, another feature that distinguishes the two classes of importers is a lack of a substrate binding sites (SBS) in the TMDs of type II importers ([@bib20]).

Type I importers mediate the translocation of small molecules such as ions, amino acids, small peptides, and mono- and oligosaccharides, and are characterized by a broad range of binding affinities ([@bib3]). Structural and biophysical studies have shown that type I importers employ an alternating access transport model in which conformational changes expose the SBS to alternate faces either side of the membrane ([@bib7]). In the resting state, the transporter has an inward-facing conformation, which changes to outward-facing once the substrate-loaded binding protein interacts with the periplasmic face. This change of conformation allows substrate release from the SBP, and passage through the TMDs into the SBS. ATP hydrolysis then powers the opening of the NBDs, and the substrate is released into the cytoplasm. Previous studies have indicated that there are subtle differences in the transport mechanism, even within the same class of importers. The type I maltose ABC importer MalFGK~2~ was shown to bind to its cognate SBP both in the presence and in the absence of maltose, and in both apo and ADP-bound states ([@bib4]). By contrast, surface plasmon resonance studies indicate that while molybdate is required to initiate the binding of the SBP in *Archaeoglobus fulgidus* ModBC-A, this is not the case for *Haemophilus influenzae* ModBC-A, resulting in substrate-dependent mechanistic differences between the two transporters ([@bib41]).

Type II importers are responsible for the high-affinity uptake of larger molecules, such as heme and vitamin B~12~, as well as smaller ones, including inorganic ions ([@bib34], [@bib38]), and possess a more complex mechanism of transport than type I importers. The X-ray structure of the entire BtuCD-F complex revealed critical interactions between the transporter and the SBP and shed light on the post-translocation conformation of the complex ([@bib16]). The crystal structures of AMP-PNP-bound BtuCD-F and BtuCD, provide mechanistic details of the ATP-powered release of vitamin B~12~ into the cytoplasm ([@bib20], [@bib21]). These structures suggest that, upon ATP binding, the transmembrane helices undergo a rearrangement to create a cleft, which temporarily is able to accommodate substrate. The absence of substrate-bound co-crystal structures, however, limits detailed knowledge of the transport cycle. Moreover, recent studies provided insights into the effects of ATP binding and hydrolysis on complex formation which led to differing conclusions. Specifically, microscale thermophoresis assays showed that ATP binding and hydrolysis strengthen the interaction between BtuCD and BtuF ([@bib21]). By contrast, single-molecule fluorescence imaging revealed that membrane-embedded BtuCD formed a stable complex with BtuF and found that addition of ATP alters the interaction between the two proteins ([@bib12]). Given the fact that the molecular details of the coupled effect of substrate and ATP binding remain unclear ([@bib23], [@bib17], [@bib18]) we set out to resolve these effects for these two importers using native mass spectrometry (MS), a technique that enables the analysis of the subunit stoichiometry and ligand binding properties of membrane proteins encapsulated in detergents micelles ([@bib43], [@bib11]). Native MS can also be used to report on the population of different complexes in solution by comparing the intensities of ligand-bound charge states within a particular protein system ([@bib33], [@bib29], [@bib5], [@bib45]).

The first native MS experiments were developed and applied to BtuCD and revealed that the non-covalent tetramer could be preserved after release from detergent micelles with post-translational modifications and nucleotide binding intact ([@bib1]). At that time, it was not possible, however, to capture interactions with the substrate binding protein BtuF. To do this, MS conditions needed to be further developed to maintain interactions between transmembrane subunits with both cytoplasmic and periplasmic subunits. To maintain interactions either side of the membrane we optimized further MS conditions and selected ModBC-A from *A. fulgidus* and BtuCD-F from *E. coli* as representatives of type I and type II importer families, respectively ([Figure 1](#fig1){ref-type="fig"}A). Following purification of wild-type ModBC, BtuCD, and their respective SBPs, we investigated their lipid binding properties, as well as the effect of substrate, and ATP binding and hydrolysis on complex formation and dissociation of these ABC importers.Figure 1Structures of BtuCD-F and ModBC-A and Their Respective Mass Spectra(A) X-ray crystal structures of BtuCD-F (left, PDB: [2QI9](pdb:2QI9){#intref0055}) and ModBC-A (right, PDB: [2ONK](pdb:2ONK){#intref0060}) visualized using PyMol (Schrödinger).(B) Mass spectrum of BtuCD-F reveals a charge state series consistent with the mass of the tetrameric transporter (BtuC~2~D~2~) bound to the SBP (BtuF) (BtuC~2~D~2~-F) a smaller population of uncomplexed transporter (BtuC~2~D~2~ red peaks) is also apparent. Different lipid species, primarily LPS, are bound to the transporter both in the presence and the absence of the SBP (light blue peaks).(C) Mass spectrum of ModBC-A shows a charge state series consistent with the tetrameric transporter bound to SBP and molybdate with different lipid-bound species primarily LPS (light blue peaks). Theoretical and observed molecular masses of all species are presented in [Table 1](#tbl1){ref-type="table"}.Table 1Theoretical and Observed Masses of all Species Presented in the Current StudySpeciesTheoretical Mass (Da)Observed Mass (Da)Difference (Da)BtuCD128,839128,837−2ModBC115,011115,015+4BtuF29,41429,412−2BtuF⋅Vitamin B~12~30,77030,768−2BtuF⋅Cyanocobinamide30,43030,427−3ModA38,58438,583−1BtuCD-F158,253158,251−2BtuCD-F⋅2ADP159,107159,105−2BtuCD-F⋅2AMP-PNP159,313159,320+7ModBC-A⋅MoO~4~^2--^153,763153,766+3ModBC-A⋅MoO~4~^2−^⋅2ADP154,615154,623+8[^3]

Results {#sec2}
=======

Substrates Have Different Effects on the Formation of Type I and Type II Transporter Complexes {#sec2.1}
----------------------------------------------------------------------------------------------

We expressed and purified BtuCD following established protocols (see the [STAR Methods](#sec4){ref-type="sec"} section) ([@bib25]). We then performed a detergent screen to establish conditions that preserve the complex for native MS ([@bib22]). Selecting detergents from different classes, we found that tetraethylene glycol monooctyl ether (C~8~E~4~) both solubilized the membrane protein complex and yielded well-resolved charge states corresponding to the mass of intact BtuCD ([Figure S1](#mmc1){ref-type="supplementary-material"}A and [Table 1](#tbl1){ref-type="table"}). Adducts were also observed consistent with the presence of co-purified lipids, particularly lipopolysaccharides (LPS), an observation typical of the native mass spectra of membrane proteins ([@bib44], [@bib5]) and in particular of ABC transporters ([@bib2], [@bib28]).

Having optimized the MS conditions to detect BtuCD, we then purified BtuF ([@bib16]) ([Figure S3](#mmc1){ref-type="supplementary-material"}A) and studied its binding properties to BtuCD. To form the BtuCD-F complex, we incubated BtuF with BtuCD and introduced this solution to the mass spectrometer. We observed a new charge state series corresponding to the intact BtuCD-F (\>90%) complex ([Figure 1](#fig1){ref-type="fig"}B). Associated with the charge state series for the intact complex is a series of satellite peaks indicating that the complex has retained binding to membrane lipids.

For ModBC-A, we expressed and purified ModBC as described previously ([@bib14]) and performed a detergent screen to obtain well-resolved mass spectra. We selected C~8~E~4~ to replicate the MS conditions used for BtuCD and similarly the experimental mass is consistent with the intact tetramer of ModBC with various associated phospholipids and LPS ([Figure S1](#mmc1){ref-type="supplementary-material"}B). Despite the fact that BtuCD and ModBC were purified using different detergents the same type of bulk lipids from *E. coli* remained bound to the transporters ([Figure S2](#mmc1){ref-type="supplementary-material"}).

To record the mass spectrum of the entire ModBC-A complex we purified ModA ([@bib14]) ([Figure S3](#mmc1){ref-type="supplementary-material"}B) and incubated it with a solution containing ModBC. The most abundant species was ModBC; only a small population had formed a complex with ModA. Moreover, mass spectra also indicated the presence of free ModA in solution, confirming that the complex had not formed ([Figure S1](#mmc1){ref-type="supplementary-material"}C) and implying that additional components are required to achieve full complexation in solution. We reasoned that substrate may be required and added an excess of sodium molybdate to a solution of ModA before buffer exchange and then incubated this solution with ModBC. Under these conditions, we observed a different pattern of charge states whose deconvolution yields a mass consistent with the presence of 100% full ModBC-A complex ([Figure 1](#fig1){ref-type="fig"}C). Considering the deconvoluted masses of the individual proteins and the mass of the full complex we calculated a difference of 168 Da, consistent with the presence of molybdate ions bound to the intact complex (calculated as 160 Da). Additional satellite peaks, similar to those observed for ModBC, were assigned to lipid-bound species, associated with the full ModBC-A⋅MoO~4~^2−^ complex.

We suggest that type I importers, exemplified here by ModBC-A, have low affinity for their cognate SBP and only the addition of the substrate triggers the formation of the full complex. By contrast, type II importers, exemplified here by BtuCD-F, bind readily to their cognate SBP, even in the absence of substrate. Taken together, these results imply that the two transporters examined here have different affinities toward their respective SBPs.

Vitamin B~12~ and Cyanocobinamide Destabilize the BtuCD-BtuF Interaction {#sec2.2}
------------------------------------------------------------------------

Having demonstrated that BtuCD and BtuF form a stable complex, the next question was to examine whether vitamin B~12~ had an effect on the stability of the BtuCD-F complex. We supplemented BtuF with an excess of vitamin B~12~ and recorded a mass spectrum of the BtuF:vitamin B~12~ complex ([Figure 2](#fig2){ref-type="fig"}A, inset). We then incubated the vitamin B~12~-loaded BtuF with a solution of BtuCD. Interestingly, vitamin B~12~ binding was not detected in either complex (BtuCD or BtuCD-F) ([Figure 2](#fig2){ref-type="fig"}A). Absence of vitamin B~12~ is in line with the previous observation that the TMDs of BtuCD lack a high-affinity SBS ([@bib20]). The binding of vitamin B~12~ is likely transient, making it difficult to detect with biophysical methods. We noticed, however, an increase in the intensity of charge states corresponding to uncomplexed BtuCD (45%), compared with BtuCD-F in the absence of substrate wherein only 10% of BtuCD was observed ([Figures 2](#fig2){ref-type="fig"}A and [1](#fig1){ref-type="fig"}B, red peaks). The presence of vitamin B~12~, although not detected directly within the complex, destabilizes the interactions between the SBP and the transporter.Figure 2BtuCD-F Is Destabilized by Vitamin B~12~ and Cyanocobinamide(A) Mass spectrum of BtuCD-F recorded after addition of 2 mM vitamin B~12~ to BtuF before buffer exchange. An increase in the intensity of the charge states corresponding to uncomplexed BtuCD (red peaks 45% with respect to BtuCD-F 100%) is observed in the presence of vitamin B~12~ (purple peak) compared with in the absence of ligand (cf. [Figure 1](#fig1){ref-type="fig"}B). The inset shows the mass spectrum of BtuF-vitamin B~12~ complex after addition of 2 mM vitamin B~12~.(B) Mass spectrum of BtuCD-F after addition of 2 mM dicyanocobinamide to BtuF before buffer exchange. The ratio of BtuCD (red peaks 44% with respect to BtuCD-F 100%) is closely similar to the extent of complex formation in the presence of vitamin B~12~. The inset shows the mass spectrum of BtuF-cyanocobinamide complex after addition of 2mM dicyanocobinamide.(C) Mass spectrum of BtuCD-F after addition of 2 mM vitamin B~9~ to BtuF before buffer exchange. The ratio of BtuCD (red peaks 15% with respect to BtuCD-F 100%) in the presence of vitamin B~9~ is closely similar to the extent of complex formation in the absence of ligand. Data are represented as means ± SD (n = 3).(D) Chemical structures of the molecules used for the binding experiments.

Recently, it has been reported that cyanocobinamide, a closely related analog of vitamin B~12~, is imported by BtuCD-F, and the co-crystal structure of BtuF-cyanocobinamide has been determined ([@bib30]). To further investigate this interaction using native MS we added an excess amount of dicyanocobinamide to BtuF alone and observed two series of charge states, corresponding to apo-BtuF and BtuF-cyanocobinamide ([Figure 2](#fig2){ref-type="fig"}B, inset), confirming binding to BtuF in line with previous results ([@bib30]). We then incubated dicyanocobinamide-loaded BtuF with a solution of BtuCD and observed that the BtuCD and BtuCD-F peak intensities had increased to similar values as those observed when vitamin B~12~ was added ([Figure 2](#fig2){ref-type="fig"}B), indicating that the complex was destabilized.

The destabilization effect of vitamin B~12~ on the complex was further confirmed by using a molecule with a different structure, vitamin B~9~ (folic acid, [Figure 2](#fig2){ref-type="fig"}B). Under analogous conditions to those used for vitamin B~12~, vitamin B~9~ did not affect the stability of the complex BtuCD-F with little dissociation of BtuCD (15%) ([Figure 2](#fig2){ref-type="fig"}C). The absence of any effects of vitamin B~9~ highlights the specificity of the effect for vitamin B~12~ and cyanocobinamide, which, upon binding, induce dissociation of BtuF. We conclude therefore that type II importer BtuCD-F exists in solution as a stable complex with its SBP, even in the absence of ligands. Addition of substrates to this type II importer has a disruptive effect on protein interactions leading to reduced stability of the substrate binding protein.

ATP Binding Acts Synergistically with the Substrate to Decrease BtuCD-BtuF Stability {#sec2.3}
------------------------------------------------------------------------------------

To gain further insights into the vitamin B~12~ translocation mechanism we studied the effects of ATP binding and turnover on complex stability. We added an excess of ATP/Mg^2+^ to a solution of BtuCD, prior to buffer exchange into MS buffer, and incubated it with a solution of BtuF following the same protocol as above. After a 10-min incubation time the mass spectrum indicates the presence of three BtuCD-F species in solution: the apo form and two nucleotide-bound states with one and two ADP molecules bound, referred to as apo-BtuCD-F, BtuCD-F⋅1ADP, and BtuCD-F⋅2ADP, respectively ([Figures 3](#fig3){ref-type="fig"}A and [S4](#mmc1){ref-type="supplementary-material"}A). To distinguish the effect of binding from hydrolysis, we carried out analogous experiments in the presence of AMP-PNP, a non-hydrolysable ATP analog. We observed apo-BtuCD-F as well as a population assigned to BtuCD-F⋅2AMP-PNP ([Figures 3](#fig3){ref-type="fig"}B and [S4](#mmc1){ref-type="supplementary-material"}B). Interestingly, while BtuCD-F⋅2ADP is predominant, apo-BtuCD-F is more abundant than BtuCD-F⋅1ADP, and in the presence of AMP-PNP no population of a BtuCD-F bound to a single AMP-PNP species was detected. This binding pattern of nucleotides was found to be insensitive to longer incubation periods suggesting that equilibrium had been reached. Overall, our findings suggest that binding of the first nucleotide increases the affinity of the protein for the second one, a characteristic feature of cooperative binding ([@bib9]). Moreover, in both cases, BtuCD was bound to the two different nucleotides in a similar fashion to that observed for the full complex. The overall population of free BtuCD and corresponding adducts was found to increase after addition of nucleotides, with the BtuCD/BtuCD-F ratio being in the range of 40%--45% in the presence of ATP or AMP-PNP ([Figures 3](#fig3){ref-type="fig"}A, 3B, [S4](#mmc1){ref-type="supplementary-material"}A, and S4B). Such an increase in BtuCD-related charge states is analogous to the situation observed for vitamin B~12~, thus indicating that a destabilizing effect is also induced by nucleotide binding.Figure 3Effect of Nucleotides on BtuCD-F and ModBC-A Complex Formation(A) Deconvoluted masses of the spectrum of BtuCD-F recorded after addition of 5 mM ATP to BtuCD before buffer exchange. The presence of ADP-bound species of both BtuCD-F and BtuCD are observed with similar ratios. The relative abundance of BtuCD in this spectrum is 40% of the BtuCD-F signal.(B) Deconvoluted masses of the spectrum of BtuCD-F recorded after addition of 5 mM AMP-PNP to BtuCD before buffer exchange. Also in this case, AMP-PNP-bound species are detected. The relative abundance of BtuCD in this spectrum is 43% of the BtuCD-F signal.(C) Deconvoluted masses of the spectrum of ModBC-A recorded following the addition of 10 μM ATP to ModBC after buffer exchange. ModBC-A species bound to zero, one and two ADP molecules are observed and no ModBC alone is detected.

To study the combined effect of substrate and nucleotide, we added solutions of ATP and vitamin B~12~ simultaneously to the BtuCD-F complex. Interestingly, we noticed that the increase in the intensity of free BtuCD charge states was even more significant when both ligands are present ([Figures S4](#mmc1){ref-type="supplementary-material"}A, S4C, and [1](#fig1){ref-type="fig"}B), implying a synergistic effect of binding both ATP and vitamin B~12~. Our data also show that the cooperativity in ATP binding observed above is retained in the presence of vitamin B~12~ ([Figure S4](#mmc1){ref-type="supplementary-material"}C). The results obtained from the addition of ATP, AMP-PNP, and ATP-vitamin B~12~ suggest a mechanism whereby ATP binding causes a conformational change that leads to a decrease in affinity for the substrate binding protein. While the AMP-PNP experiments cannot exclude a contribution from ATP hydrolysis, in destabilizing the complex *in vivo*, they do demonstrate that nucleotide binding alone is sufficient to destabilize the interaction between BtuCD and BtuF.

ATP Binding Does Not Alter ModBC-ModA Interactions {#sec2.4}
--------------------------------------------------

To evaluate the impact of ATP binding and hydrolysis on the ModBC-A complex we first added an excess of ATP to a solution of ModBC before exchanging into an MS-compatible buffer. We then incubated this solution with ModA. The resulting mass spectrum did not display any nucleotide binding, implying that all ATP had been removed during buffer exchange. To observe nucleotide binding, we added excess ATP to ModA pre-loaded with sodium molybdate and recorded the mass spectrum under optimized conditions. Three populations of ModBC-A⋅MoO~4~^2−^ are observed: an apo form and the species bound to one and two ADP molecules ([Figures 3](#fig3){ref-type="fig"}C and [S5](#mmc1){ref-type="supplementary-material"}). The distribution of the three species is different from BtuCD-F; indeed, the apo form is less abundant, thus no cooperativity is observed in ATP/ADP binding to ModBC-A⋅MoO~4~^2−^, indicating little or no cooperativity of the two ATP binding events. Moreover, we did not observe additional charge states corresponding to ModBC, implying that ATP did not influence the ModBC-A/ModBC interactions significantly.

Based on our results we propose that nucleotide binding has a different impact on type I and type II transporters examined here. In the type I transporter, ATP did not perturb interactions between the transporter and its cognate SBP. Nucleotide binding was found to be independent of the effect of substrate, the latter being pivotal for complex formation. By contrast, ATP binding and hydrolysis modulates interactions between the transporter and the SBP in the transport cycle of the type II importer. In addition, ATP binding follows different patterns in the two complexes: while we observed cooperative ATP binding in the case of BtuCD-F, we did not observe cooperativity for ModBC-A. While we cannot rule out cooperativity of nucleotide binding for type I importers we speculate that differences in the TMD structures of the two transporters may influence interactions and crosstalk within the NBDs.

Discussion {#sec3}
==========

In the current study, we employed native MS to observe membrane protein complexes developing the approach further to capture ABC importers bound to their cognate substrate binding proteins. Capturing these complexes allowed us to explore the influence of ligands on their stability. Specifically, we showed that the two ABC importers were associated with similar lipids even when extracted and purified in different detergents. Moreover, the cohort of bound lipids did not change significantly when binding of ATP or substrates or during complex formation. These observations suggest that the transporters do not have a specific preference for the bulk lipids that surround them, in contrast to the flippase TmrAB investigated previously, wherein negatively charged lipids bound tightly to the protein ([@bib2]). We also demonstrated that binding of BtuCD-F substrates, vitamin B~12~ and cyanocobinamide, led to disruption of the BtuCD-BtuF complex, whereas molybdate binding is required to promote docking of ModA onto ModBC. The dissociation of BtuCD-F complex is explained by the fact that, once vitamin B~12~-loaded BtuF docks on to BtuCD, insufficient space is available to accommodate the bulky B~12~ substrate ([Figure 2](#fig2){ref-type="fig"}B). In addition, the ModBC-A complex is stable, regardless of the presence of ATP, while BtuCD-F is destabilized by binding of ATP or its non-hydrolysable analog AMP-PNP. Moreover, the disruptive effect of vitamin B~12~ is enhanced by the presence of nucleotides, consistent with the ligands acting synergistically to promote substrate release. We also highlighted further differences in ATP binding mechanisms between type I and type II transporters. While no significant cooperativity was detected for ModBC-A, when binding to nucleotides, for BtuCD-F the first ATP binding event facilitates the second in accordance with typical cooperative binding models.

On the basis of our results, and with contributions from previous structural and biophysical data ([@bib16], [@bib41], [@bib23], [@bib17], [@bib18], [@bib20], [@bib21], [@bib12]), we present two different transport models for type I and type II ABC importers.

For the type I importer ModBC-A our data show that in the absence of substrate the extent of SBP binding onto the transporter is very low; essentially, there is no complex formation ([Figure 4](#fig4){ref-type="fig"}A, state I). Binding of substrate results in increased complex formation, triggering the docking of the SBP onto the transporter, trapping the substrate and beginning of the transport cycle ([Figure 4](#fig4){ref-type="fig"}A, state II). This interaction is then thought to initiate a conformational rearrangement, converting the TMDs from an inward- to an outward-facing conformation ([@bib32]), and likely forming a tunnel which allows the translocation of the substrate from the SBP to the SBS, located in the TMDs ([Figures 4](#fig4){ref-type="fig"}A, state III and [1](#fig1){ref-type="fig"}B). Subsequent ATP binding induces a further rearrangement to an inward-facing conformation causing dissociation of the substrate from the SBS and its release into the cytoplasm ([Figure 4](#fig4){ref-type="fig"}A, state IV). The translocation of the substrate and dissociation of ADP from the NBDs reset the transporter to the initial state ([Figure 4](#fig4){ref-type="fig"}A, state I). Together these steps are consistent with the alternating access transport mechanism in which conformational changes expose the SBS to alternate faces either side of the membrane ([@bib7], [@bib19]).Figure 4Transport Models for Type I Importer ModBC-A and TYPE II IMPorter BtuCD-F(A) Transport model for ModBC-A. The formation of the complex in the absence of molybdate is unfavorable (state I). Binding of molybdate triggers the docking of ModA onto ModBC (state II). Following a rearrangement of the TMDs, molybdate moves toward the SBS (state III). ATP binding and hydrolysis triggers a further conformational change that translocate the substrate into the cytoplasm (state IV). The release of ADP resets the transporter to the resting state (state I).(B) Transport model for BtuCD-F. BtuCD and BtuF form a stable complex even in the absence of vitamin B~12~ (state I). ATP binds cooperatively, leading to a partial displacement of BtuF from BtuCD (state II). When vitamin B~12~ is available, a transient BtuCD-F⋅2ADP⋅B~12~ complex is formed (state III). This unstable conformation is relaxed through ADP and Pi dissociation, followed by vitamin B~12~ release (state IV) leading to the resetting of the transporter.

The type II importer (BtuCD-F) studied here follows a different cycle wherein the transporter complex with the SBP is stable in solution, even in the absence of substrate ([Figures 4](#fig4){ref-type="fig"}B state I and [1](#fig1){ref-type="fig"}B). Following the cooperative binding of ATP, the TMDs undergo conformational changes leading to a disruption of the interactions with the SBP. The reduction in the level of complexation does not necessarily imply that appreciable dissociation takes place *in vivo*, rather it suggests that the complex is undergoing conformational changes whereby binding of SBP to the TMDs is perturbed. We propose a model whereby the SBP-bound transporter partially opens upon nucleotide binding, consistent with the increased levels of uncomplexed transporter observed by MS ([Figure 4](#fig4){ref-type="fig"}B state II) ([@bib12]). Moreover, earlier studies showed that type II importers are characterized by a high level of futile ATP hydrolysis, with a high ATP:vitamin B~12~ transport ratio ([@bib6], [@bib40]). Once the complex opens, substrate is bound ([Figure 4](#fig4){ref-type="fig"}B, state III) and partially accommodated in a cleft formed by the helices present in the TMDs ([@bib21]) as a consequence of nucleotide binding. However, the presence of substrate and the full occupancy of nucleotide binding sites has a synergistic effect rendering the full complex more susceptible to dissociation, leading to the dissociation of ADP and Pi, which triggers the subsequent translocation of the substrate into the cytoplasm ([Figure 4](#fig4){ref-type="fig"}B, state IV). The presence of substrate decreases the stability of the complex; therefore, a critical factor in the release of the substrate to the cytoplasm is the achievement of the state of minimal energy represented by the SBP-bound transporter ([Figure 4](#fig4){ref-type="fig"}B state I).

Over the past years, biochemical techniques such as surface plasmon resonance ([@bib41], [@bib35]) and single-molecule fluorescence resonance energy transfer ([@bib42], [@bib15]) have been used to study the binding of ligands on ABC transporters, providing valuable information about their influence on the mechanism of transport. The MS approach we have applied here, therefore, complements earlier studies ([@bib23], [@bib21], [@bib12]) by providing evidence of the role of substrate and ATP in complex formation and substrate transport across the lipid bilayer. These results further indicate that there is an essential difference between type I and type II ABC importers examined here. Moreover, ABC transporters have a pivotal role in bacterial life and therefore represent optimal targets for the development of antimicrobial drugs ([@bib31]). Given the increasing number of multidrug-resistant bacteria, there is an urgent need for new strategies targeting less explored pathways. Hence, better understanding of ABC importers mechanisms may prove useful for the development of novel therapeutics.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Bacterial and Virus Strains**BL21 (DE3)New England BiolabsCat\# C2527IStellar Competent CellsTakaraCat\# 636763**Chemicals, Peptides, and Recombinant Proteins**In-Fusion cloning kitClonetechCat \# 638909n-Dodecyl-β-D-Maltopyranoside (DDM)AnatraceCat\# D310SOctaethylene Glycol Monododecyl Ether (C12E8)AnatraceCat\# O330n-Dodecyl-N,N-Dimethylamine-N-Oxide (LDAO)AnatraceCat\# D360Tetraethylene Glycol Monooctyl Ether (C8E4)AnatraceCat\# T350Ammonium acetateSigma AldrichCat\# A2706Vitamin B12Sigma AldrichCat\# V2876DicyanocobinamideSigma AldrichCat\# C3021Folic Acid (Vitamin B9)Sigma AldrichCat\# F7876Adenosine 5'-triphosphate (ATP)Sigma AldrichCat\# A26209Magnesium chlorideSigma AldrichCat\# M8266Adenosine 5'-(β,γ-imido)triphosphate (AMP-PNP)Sigma AldrichCat\# A2647Sodium molybdateSigma AldrichCat\# 737860**Deposited Data**Crystal structure of *A. fulgidus* ModBC-A[@bib14]PDB: [2ONK](pdb:2ONK){#intref0010}<https://www.rcsb.org/structure/2ONK>Crystal structure of *E. coli* BtuCD-F[@bib16]PDB: [2QI9](pdb:2QI9){#intref0020}\
<https://www.rcsb.org/structure/2QI9>**Recombinant DNA**pET19b-ModBCGift from Kaspar LocherN/ApET19b-BtuCDGift from Kaspar LocherN/AModA (aa 32-342) gene fragmentThis paperN/ABtuF (aa 23-266) gene fragmentThis paperN/ApET28aNovagenCat\# 69864-3pET22bNovagenCat\# 69744-3**Software and Algorithms**UniDec[@bib27]<http://www.unidec.chem.ox.ac.uk>PyMolSchrödinger, LLC Version 1.8[www.sourceforge.net/projects/pymol](http://www.sourceforge.net/projects/pymol){#intref0035}XcaliburThermo ScientificN/A**Other**Clark Borosilicate Standard Wall CapillariesHarvard ApparatusCat \#30-0044PicoTip Emitter SilicaTipNew ObjectiveCat \#FS360-20-10

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by Carol V. Robinson (<carol.robinson@chem.ox.ac.uk>).

Method Details {#sec4.3}
--------------

### Plasmid Preparation and Protein Expression {#sec4.3.1}

ModA plasmid was obtained by inserting the gene fragment encoding the predicted mature part of the periplasmic binding-protein (amino acids 32-342) into a modified pET-28a expression vector (Novagen) between BamHI and XhoI cloning sites, using an In-Fusion cloning kit (Clonetech). The modified pET-28a contained an N-terminal decahistidine affinity tag followed by a TEV protease cleavage site. The BtuF plasmid was constructed by inserting the gene fragment containing amino acids 23-266 into pET-22b expression vector (Novagen) between NcoI and XhoI cloning sites. The plasmids used for over-expression of *E. coli* BtuCD and *A. fulgidus* ModBC were a kind gift from Kaspar Locher (ETH Zurich). All plasmids were amplified by transforming them into *E. coli* Stellar Competent Cells (Takara) and the DNA sequences were verified by Sanger sequencing.

For each protein, the plasmid was transformed in *E. coli* BL21(DE3) (New England Biolabs). Several colonies were inoculated into 100 ml LB media and grown overnight at 37°C. One litre of LB in 2 litre shaker flasks was inoculated with 7 ml of overnight culture and grown at 37°C until the culture reached OD600 nm (OD600) between 0.6 and 0.8. Isopropyl-β-D-1-thiogalactopyranoside (IPTG) was added to the culture at a final concentration of 0.5 mM and grown for 3 h at 37°C. Cells were collected by centrifugation at 5,000xg for 10 min at 4°C. Cell pellets were resuspended in buffer containing 150mM NaCl, 20 mM Tris (pH 7.5) and stored at −80°C.

### Purification of Soluble Proteins {#sec4.3.2}

#### ModA {#sec4.3.2.1}

Resuspended cells were thawed and supplemented with an EDTA-free protease inhibitor cocktail (Roche). The cell suspension was passed several times through an M-110 PS microfluidizer (Microfluidics) at 15,000 psi. Insoluble material was pelleted by centrifugation at 20,000xg for 20 min at 4°C. The supernatant was filtered before loading onto a 5 ml HisTrap-HP column (GE Healthcare, Piscataway, NJ) equilibrated in 200 mM NaCl, 20 mM Hepes (pH 7.5), 10% glycerol and 20 mM imidazole. After the clarified supernatant was loaded, the column was initially washed with 50 ml of 200 mM NaCl, 20 mM Hepes (pH 7.5), 10% glycerol and 20 mM imidazole, and washed again with 50 ml of 200 mM NaCl, 20 mM Hepes (pH 7.5), 10% glycerol and 80 mM imidazole. The bound protein was eluted with 200 mM NaCl, 20 mM Hepes (pH 7.5), 10% glycerol and 500 mM imidazole. Peak fractions were pooled, incubated with TEV protease and dialysed against 200 mM NaCl, 20 mM Hepes (pH 7.5), and 10% glycerol. The protein was then concentrated and loaded onto the Superdex 200 size exclusion chromatography (SEC) column in 200 mM NaCl, 20 mM Hepes (pH 7.5), and 10% glycerol.

#### BtuF {#sec4.3.2.2}

The protein was purified following the same protocol as ModA, except that the final buffer contains also 10 mM DTT.

### Purification of Membrane Proteins {#sec4.3.3}

Resuspended cells were thawed and supplemented with EDTA-free protease inhibitor cocktail (Roche). The cell suspension was passed several times through an M-110 PS microfluidizer (Microfluidics) at 15,000 psi. Insoluble material was pelleted by centrifugation at 20,000xg for 20 min at 4°C. The supernatant was ultracentrifuged at (200,000xg for 1h), and the membrane fractions were collected. Membranes were resuspended in ice-cold buffer containing 150 mM NaCl, 20 mM Tris (pH 7.5) and 20% glycerol. Resuspended membranes were used either directly or flash frozen in liquid nitrogen and stored at −80°C.

#### ModBC {#sec4.3.3.1}

The protein was solubilized from the membrane fraction with 150 mM NaCl, 20 mM Tris (pH 7.5), 20% glycerol, 1% n-Dodecyl-β-D-Maltopyranoside (DDM, Anatrace) and 1% octaethylene glycol monododecyl ether (C~12~E~8~, Anatrace) for 1h at 4°C. Extracted membrane proteins were clarified by centrifugation at 20,000xg for 20 min at 4°C. Supernatant was filtered before loading onto a 5 ml HisTrap-HP column (GE Healthcare, Piscataway, NJ) equilibrated in 150 mM NaCl, 20 mM Tris (pH 7.5), 10% glycerol, 20 mM imidazole and 0.01% C~12~E~8~. After the clarified supernatant was loaded, the column was initially washed with 50 ml of 150 mM NaCl, 20 mM Tris (pH 7.5), 10% glycerol, 20 mM imidazole and 0.01% C~12~E~8~, and washed again with 50 ml of 150 mM NaCl, 20 mM Tris (pH 7.5), 10% glycerol, 80 mM imidazole and 0.01% C~12~E~8~. The bound protein was eluted with 150 mM NaCl, 20 mM Tris (pH 7.5), 10% glycerol, 500 mM imidazole and 0.01% C~12~E~8~. The protein was concentrated to 2.5 ml an Amicon Ultra-15 concentrator unit (Millipore) with a molecular cut-off of 100 kDa and buffer exchanged to 150 mM NaCl, 20 mM Tris (pH 7.5), 0.5 mM EDTA, 10% glycerol and 0.01% C~12~E~8~ using PD-10 desalting column. The protein was further concentrated and loaded onto the Superdex 200 size exclusion chromatography (SEC) column in 150 mM NaCl, 20 mM Tris (pH 7.5), 0.5 mM EDTA, 10% glycerol and 0.01% C~12~E~8~.

#### BtuCD {#sec4.3.3.2}

The protein was purified following the same protocol as ModBC, except that protein was solubilized in 1% n-Dodecyl-N,N-Dimethylamine-N-Oxide (LDAO, Anatrace) and all the buffers were supplemented with 0.05% LDAO.

### Native MS Experiments {#sec4.3.4}

Purified membrane proteins were buffer exchanged into MS Buffer (two times the CMC of detergent of interest and 200 mM ammonium acetate) using a centrifugal buffer exchange device (Micro Bio-Spin 6, Bio-Rad) as previously described ([@bib22]). The best quality mass spectra of all membrane proteins were obtained using 0.5% C~8~E~4~ (Anatrace) as detergent.

Soluble proteins were buffer exchanged into 200 mM ammonium acetate (Sigma Aldrich) using the same method. The freshly buffer-exchanged proteins were kept on ice, with protein concentration measured as before. The protein samples were diluted as desired in 200 mM ammonium acetate buffer with detergent as necessary and loaded into a gold-coated capillary Clark borosilicate capillary (Harvard Apparatus) prepared in the laboratory ([@bib13]). The experiment was performed using a modified Q-Exactive hybrid quadrupole-Orbitrap mass spectrometer (Thermo Fisher Scientific, Bremen, Germany), optimised for analysing protein complexes of high mass and membrane proteins ([@bib11]). The instrument was calibrated using caesium iodide solution. Typically, 2 μl of buffer exchanged protein solution was electrosprayed from gold-plated borosilicate capillaries prepared in house. The instrument parameters for MS are: 1.2kV capillary voltage, S-lens RF 100%, quadrupole selection from 1,000 to 15,000 m/z range, collisional activation in the HCD cell 0-300 V, argon UHV pressure 1.2^∗^10^-9^ mbar and 30 to 200°C capillary temperature, resolution of the instrument at 17,500 at m/z = 200 (a transient time of 64 ms) and ion transfer optics (injection flatapole, inter-flatapole lens, bent flatapole, transfer multipole: 8, 7, 6, 4 V respectively). The noise level was set at 3 rather than the default value of 4.64. Where required, baseline subtraction was performed to achieve a better-quality mass spectrum. Data were analysed using the Xcalibur 3.0 (Thermo Scientific) and UniDec ([www.unidec.chem.ox.ac.uk](http://www.unidec.chem.ox.ac.uk){#intref0045}) software packages. Theoretical and observed molecular masses of all species are described in [Table 1](#tbl1){ref-type="table"}.

#### Complex Formation Experiments {#sec4.3.4.1}

To allow the observation of BtuCD-F spectrum, it was necessary to incubate solutions of the two proteins in a 1:2 molar ratio (BtuF:BtuCD). In order to observe the effect of vitamin B~12~ on complex formation, 2 mM vitamin B~12~ (Sigma Aldrich) was added to a solution of BtuF before buffer exchange, then the solutions containing vitamin B~12~-loaded BtuF and BtuCD were incubated and analysed as described above. Experiments with cyanocobinamide and vitamin B~9~ (Sigma Aldrich) were performed in the same way as described above. To analyse the impact of ATP binding and hydrolysis, 5 mM ATP (Sigma Aldrich) and 5 mM MgCl~2~ (Sigma Aldrich) were added to a solution of BtuCD before buffer exchange; then solutions containing BtuF and ADP-bound BtuCD were mixed and analysed as described above. The AMP-PNP experiments were performed by adding 5 mM AMP-PNP (Sigma Aldrich) to a solution of BtuCD before buffer exchange; then solutions containing BtuF and AMP-PNP-bound BtuCD were mixed and analysed as previously described. To assess the effect of both vitamin B~12~ binding and ATP binding and hydrolysis, 2 mM vitamin B~12~ was added to BtuF and 5 mM ATP was added to BtuCD before buffer exchange; then the solutions were mixed and analysed as mentioned above.

To detect the spectrum of ModBC-A in a 1:1 molar ratio was used (ModA:ModBC). Sodium molybdate (Na~2~MoO~4~, Sigma Aldrich) was added to a solution of ModA at a concentration of 5 mM, before buffer exchange. To analyse the influence of ATP-binding and hydrolysis, 5 mM ATP and 5mM MgCl~2~ were added to a solution of ModBC before buffer exchange, then the solutions were incubated and analysed following the protocol described above. The spectrum obtained did not show ADP binding. The experiment was therefore repeated using the following method: to a solution of 7 μM ModBC in MS buffer, ATP and MgCl~2~ were added to a final concentration of 10 μM. Then, MoO~4~^2-^-bound ModA and ADP-bound ModBC were incubated and analysed as described above.

### Lipidomics Analysis {#sec4.3.5}

For LC-MS/MS analysis, the phospholipids were separated on a C18 column (Acclaim PepMap 100, C18, 75 μm × 15 cm; Thermo Scientific) by Dionex UltiMate 3000 RSLC nano System connected to a hybrid LTQ Orbitrap mass spectrometer (Thermo Scientific) via a dynamic nanospray source using PicoTip Emitter SilicaTip (New Objective). A binary buffer system was used with buffer A of ACN: H~2~O (60:40), 10 mM ammonium formate, 0.1% formic acid and buffer B of IPA: ACN (90:10), 10 mM ammonium formate, 0,1% formic acid. The phospholipids were separated at 40°C with a gradient of 32% to 99% buffer B at a flow rate of 300 nl/min over 30 min. Typical MS conditions were: spray voltage of 1.8 kV and capillary temperature of 175°C. The LTQ-Orbitrap XL was operated in negative ion mode and in data-dependent acquisition with one MS scan followed by five MS/MS scans. Survey full-scan MS spectra were acquired in the Orbitrap (*m/z* 350−2,000) with a resolution of 60,000. Collision-induced dissociation (CID) fragmentation in the linear ion trap was performed for the five most intense ions at an automatic gain control target of 30,000 and a normalized collision energy of 38% at an activation of q = 0.25 and an activation time of 30 ms. Data were analysed by extracting ion chromatogram (XIC) and its area under the curve (AUC) of each cardiolipin was processed and integrated in Xcalibur3.0 (Thermo Scientific)) with 50 ppm 4 mass tolerance and 7 point Gaussian smoothing. The relative abundances of PEs and PGs in the samples were calculated based on the ratio of their AUCs to the sum of the AUCs of the phospholipids belonging to the same class.

Quantification and Statistical Analysis {#sec4.4}
---------------------------------------

All the experiments described in the paper were performed three times (*n*=3). Average values and standard deviations were calculated from at least 4 charge states in each of the three independent repeats and plotted using Microsoft Excel.
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